entertainment -WSS

entertainment

author：hotspot 2025-09-29 20:17:28 - browse：23945

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： What health policies could hitch a ride on a spending bill?

WSS

WuXi out of biotech trade group, U.S. and China relations to blame

What is STAT's opinion section for?

Type 2 diabetes prevention programs work at large scale: study

How many hemophilia patients actually want gene therapy?

John Green on his newest strategy for fighting tuberculosis

Cancer diagnosis changes perspective doctor, former hospital CEO

hotspot

entertainment

focus

Alkermes shareholders re

NIH chief: government has fallen behind pharma on clinical trials

How to save PrEP access — and even expand it

Why depression after traumatic brain injury is distinct

DIEP, the 'gold standard' of breast reconstruction, is under threat

Experimental asthma app from Apple and Anthem shows promise

The high cost of giving birth even with insurance

FDA reorg will put new emphasis on investigations, sources say

Trump demands the U.S. pay no more for drugs than other countries … again

Change Healthcare outage fallout shows need for new oversight

leisure time

Readout Newsletter: CAR

As AI in medicine takes off, can 'human in the loop' prevent harm?

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

FDA reorg will put new emphasis on investigations, sources say

Weight loss drugs should be covered by insurers, AMA says

What is STAT's opinion section for?

focus

focus

focus

focus